Fahimeh Ramezani Tehrani is an expert in Endocrinology at Shahid Beheshti University of Medical Sciences (Iran). As of October 2026, ScienceLeadR ranks Fahimeh Ramezani Tehrani in the top 1% of experts in Iran for Adnexal Diseases, Gonadal Disorders and Glucose Metabolism Disorders. Fahimeh Ramezani Tehrani has authored 258 publications, the most recent in 2026. SLR score: 808 (community average: 125). How the SLR is computed.

LeadR Profile

808 ScienceLeadR Reputation 808
Network Map

Endocrinology

Subspecialties: Public Health - Gynecology - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2009 - 2026

Source: PubMed

Shahid Beheshti University of Medical Sciences

Publications Synthesis

Sources: PubMed, OpenAlex

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Polycystic Ovary Syndrome and Subjective and Objective Assessments of Sleep Quality: A Systematic Review and Meta-Analysis.
PMID 42746131 — sleep, ovary, polycystic ovary syndrome, sleep wake disorders
Health Sci Rep20260
Endogenous Estrogen Exposure and All-Cause Mortality Among Women with Overweight or Obesity According to Metabolic Health Status: Insights from an 18-Year Prospective Cohort Study.
PMID 42741715 — mortality, estrogens, incidence, phenotype, cohort studies, health status, obesity, overweight
Int J Womens Health20260
Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.
PMID 42688833 — endometriosis, estrogens, osteoporosis, therapeutics, bone density
Front Glob Womens Health20260
Thiostrepton potentiates chemotherapy-induced cell death in cisplatin-resistant SKOV3 cells.
PMID 42323534 — cytokines, cells, catenins, stress, physiological, ovary, neoplasms, thiostrepton, drug therapy, oxidative stress, antioxidants, ovarian neoplasms, therapeutics, cell death, chemotherapy
BMC Cancer20260
Diabetes Type 2 in Women: The Impact of EndogenousOestrogen, A Population-Based Study With About 2 Decades of Follow-Up.
PMID 42673573 — diabetes mellitus, menarche, incidence, menopause, diabetes mellitus, type 2
Endocrinol Diabetes Metab20260

LeadR Networks

Main global connection map